Corvida™ is in development to be a Best-in-Class, orally administered adjunct to Type2 Diabetes management for the treatment of NAFLD and NASH (Stages F2 through F3) with no worsening of Fibrosis.
Between 30% - 40% of adults in the US have NAFLD and about 3% - 5% percent of adults have NASH, a progressive form of NAFLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality. Approximately 45% - 75% of people with Type2 Diabetes have NAFLD or NASH.
